Newport News, VA, March 1, 2023– ivWatch, LLC, the IV safety company, celebrated its 12-year anniversary and a record revenue year with a 75% increase in SmartTouch Sensor usage and a 26% increase in additional patient monitors deployed into the marketplace. The ivWatch continuous IV site monitoring system consists of a disposable miniaturized sensor that is connected to a patient monitor that notifies clinicians if fluid is leaking outside of their patient’s vein. Due to the potential severity of infiltrations, it is critical for clinicians to identify these adverse events as soon as possible to prevent patient injury.
The innovation is designed to work in tandem with the current clinical standards of periodic IV site assessments. New customers are adopting this latest technology to their work flows to help improve patient safety. Existing ivWatch users continue to invest in the SmartTouch technology, adding hospital-wide policies and protocols to complement their current nursing practices.
ivWatch technology continues to be the only product in the marketplace with the ability to detect IV infiltrations and extravasations at the earliest stages. The company was founded 12 years ago and grew its business from humble beginnings to now a global company that proudly manufactures its innovations in-house in the United States. With 64 patents, seven international distributors, five FDA 510K clearances, CE marking, and market authorization in eight areas, the company has laid a strong foundation for exponential growth in 2023.
In addition ECRI, an independent third party in healthcare research, hosted a webinar titled “In-Lab Testing: Device to Reduce Risk of IV Site Infiltrations” and a recording can be found here: https://www.ecri.org/components/HDJournal/Pages/Webcast-Device-to-Reduce-Risk-of-IV-Site-Infiltrations.aspx. For ECRI members, a copy of their Evaluation of ivWatch products can be requested from the organization through the member portal: https://www.ecri.org/search-results/member-preview/hdjournal/pages/evaluation-background-peripheral-iv-infiltration-detectors/.
For more information on how the technology works, visit: https://www.ivwatch.com/tech-overview/.
About ivWatch, LLC
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV site monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, and LinkedIn @ivWatch-LLC, or visit www.ivWatch.com.
Forward-Looking Statement:
All statements and information, other than statements of historical facts, are forward-looking statements based on a number of assumptions concerning future conditions that ultimately may prove to be inaccurate. These forward-looking statements may be identified by words such as “believe” “anticipate” “contemplate” and “expect.” Many phrases of our operations are subject to influences outside of our control. Any one or any combination of factors could have a materially adverse effect on our business, financial condition and results of operations. These factors include competitive pressures, economic conditions, governmental regulation and policies and a variety of other conditions. The forward-looking statements reflect our views and assumptions only as of the date of this presentation. We undertake no obligation to update any forward-looking statement to reflect events or circumstances after the statement’s date or to reflect unanticipated events.
MEDIA CONTACT:
Erin Wendell
erin.wendell@ivwatch.com
Mobile (410) 952-3800